{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=standard+central+line", "query": { "intervention": "standard central line" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 149, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=standard+central+line&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T15:39:56.269Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03116633", "title": "Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Inivata", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-06-30", "completion_date": "2018-12-31", "has_results": false, "last_update_posted_date": "2019-05-16", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 6, "location_summary": "Fort Smith, Arkansas • Joplin, Missouri • Springfield, Missouri + 3 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Joplin", "state": "Missouri" }, { "city": "Springfield", "state": "Missouri" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Allentown", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03116633" }, { "nct_id": "NCT01670188", "title": "SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Deep Vein Thrombosis" ], "interventions": [ { "name": "Pneumatic SCD - VenaFlow System (DJO Global)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2012-08", "completion_date": "2016-10-13", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01670188" }, { "nct_id": "NCT04203160", "title": "Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "CPI 613", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2020-06-23", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 10, "location_summary": "Tucson, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04203160" }, { "nct_id": "NCT01623583", "title": "Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Needle Phobia", "Phobic Disorders" ], "interventions": [ { "name": "Enhanced Needle Phobia Intervention", "type": "OTHER" }, { "name": "Standard Needle Phobia Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Davita Clinical Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2014-04", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2016-08-16", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 3, "location_summary": "Rancho Cordova, California • Sacramento, California • Asheville, North Carolina", "locations": [ { "city": "Rancho Cordova", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Asheville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01623583" }, { "nct_id": "NCT02722486", "title": "Use of a Vibrotactile Balance Belt System for Vestibular Rehabilitation in the Pediatric Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vestibular Diseases" ], "interventions": [ { "name": "Vestibular Rehabilitation/Balance Belt", "type": "DEVICE" }, { "name": "Standard Vestibular Rehabilitation", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 34, "start_date": "2016-03-01", "completion_date": "2023-01-01", "has_results": false, "last_update_posted_date": "2023-04-11", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722486" }, { "nct_id": "NCT06824467", "title": "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "H1 receptor antagonist", "type": "DRUG" }, { "name": "H2 receptor antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Steroid mouthwash (dexamethasone or equivalent)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 770, "start_date": "2025-04-09", "completion_date": "2032-11-09", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "San Francisco", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06824467" }, { "nct_id": "NCT05605899", "title": "Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Large B-cell Lymphoma (LBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-02-10", "completion_date": "2031-03", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05605899" }, { "nct_id": "NCT02694770", "title": "A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation" ], "interventions": [ { "name": "Neihulizumab Treatment", "type": "BIOLOGICAL" }, { "name": "Conventional Treatment", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbGenomics B.V Taiwan Branch", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-07", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2016-04-25", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02694770" }, { "nct_id": "NCT06934577", "title": "Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Eye Diseases", "Visual Impairment", "Glaucoma" ], "interventions": [ { "name": "Standard optometric examination", "type": "OTHER" }, { "name": "Technology enhanced eye disease detection protocol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2025-12-04", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 1, "location_summary": "Flint, Michigan", "locations": [ { "city": "Flint", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06934577" }, { "nct_id": "NCT07555938", "title": "Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2026-06-23", "completion_date": "2033-01-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-05T15:39:56.269Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07555938" } ] }